Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus apatinib versus camrelizumab as adjuvant therapy after curative surgery or ablation in high-risk hepatocellular carcinoma
CTR20221084Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing Camrelizumab plus apatinib with Camrelizumab (2 arms). Primary endpoint: Recurrence-free survival. Started Oct 2022; status: completed.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20221084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221084.